Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T22:13:49.827Z.
Calculation as of: 2026-10-06T22:13:49.827Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9ce6fbcd26cd45408ca5c48bb89acec7413e4f513cf2411d103b895814b8ecfc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$1.89B
EV/EBIT Ratio
251.96x
TTM Avg
240.22x
3Y Avg
240.22x
5Y Avg
240.22x
Market Cap
$1.83B
EV/EBIT Ratio
24.02x
TTM Avg
27.59x
3Y Avg
23.49x
5Y Avg
21.15x
Market Cap
$1.83B
EV/EBIT Ratio
N/A
TTM Avg
199.19x
3Y Avg
199.19x
5Y Avg
199.19x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Trevi Therapeutics, Inc. (TRVI) | $1.87B | N/A | N/A | N/A | N/A |
| Novavax, Inc. (NVAX)vs › | $1.86B | N/A | 3.63x | 3.63x | 3.63x |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 251.96x | 240.22x | 240.22x | 240.22x |
| Zymeworks Inc. (ZYME)vs › | $1.89B | N/A | 2.37x | 2.37x | 2.37x |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | N/A | N/A | N/A | N/A |
| Immunome, Inc. (IMNM)vs › | $1.85B | N/A | N/A | N/A | N/A |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.84B | N/A | N/A | N/A | N/A |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 24.02x | 27.59x | 23.49x | 21.15x |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.83B | N/A | 199.19x | 199.19x | 199.19x |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.92B | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
